Psychedelic Medicine Podcast with Dr. Lynn Marie Morski Por arte de portada

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

De: Lynn Marie Morski MD JD
Escúchala gratis

  • Resumen

  • Curious about the possible therapeutic benefits of psychedelic medicines? The Psychedelic Medicine Podcast with Dr. Lynn Marie Morski has you covered with the latest in scientific research, medical practices, and legal developments involving these substances and their incredible therapeutic potential. Covering the full range of psychedelic therapies, including psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, and more, this podcast serves as an auditory encyclopedia of information for anyone interested in learning about the safe, therapeutic uses of these medicines.
    All podcast episodes and show notes are copyright Lynn Marie Morski, 2023.
    Más Menos
Episodios
  • Psychedelic Therapy: Slow Down to Heal Faster with Sunny Strasburg, LMFT

    Psychedelic Therapy: Slow Down to Heal Faster with Sunny Strasburg, LMFT
    Jun 19 2024
    In this episode of the Psychedelic Medicine Podcast, Sunny Strasburg joins to open the conversation of leveraging lower doses of psychedelic substances for more effective healing. Sunny Strasburg, LMFT, a licensed psychotherapist, educator, and pioneering author, specializes in psychedelic therapies and training clinicians to be skilled and trauma-informed psychedelic therapists. As the founder and author of The Theradelic Approach, she equips clinicians with trauma-informed psychedelic-assisted therapy methods, blending IFS, EMDR, archetypal psychology, trauma-informed care, and her extensive experience. In this conversation, Sunny shares insights drawn from Internal Family Systems (IFS) and explores how these perspectives can help inspire more effective psychedelic work, especially with lower doses. She emphasizes the importance of adequate preparation and not over-valorizing intense psychedelic experiences, noting that these therapies themselves can be traumatic if not handled with care. Sunny also discusses how one’s own internal protectors have adaptive rolls and display a lot of compassionate intelligence, so even though these parts may initially provide a barrier to deep trauma work, it is important for therapists to work collaboratively with these parts of a client’s psyche. In closing she talks about how to better set reasonable expectations in group psychedelic therapy and retreat settings, where integration can easily turn into a competition of who had the most intense experience, with things like ego dissolution becoming the barometer for healing. In this episode you'll hear: How “protector systems” and “rubber band effects” manifest in high-dose psychedelic therapy sessionsUncovering previously unknown traumas during psychedelic therapies and how therapists can be better prepared for this situationHow therapists can skillfully work with symbolic material that arises in psychedelic journeys The importance of slowing down and letting the client guide the pace when addressing serious traumas in particularDifferences between ketamine, MDMA, and the classic psychedelics in terms of effects on the fear center of the brainLeveraging critical learning periods in therapy to reprocess traumatic memories Quotes: “Being a trauma therapist, you have to be skilled enough to know what is symbolic in a psychedelic journey, what’s a literal memory… You don’t want to do any kind of leading or prompting the client to fill in anything or directing them to anything—you’re really tracking where they are and letting them uncover their own path. Again, at the speed in which their protector system is ready for that.” [22:43] “These parts want people to remember. They want to heal, they want to let their stories be told. And so our job as therapists is to clear the clutter so we can really hear the system and trust the system. The system knows.” [28:02] “Trauma is like a sliver that’s buried in the arm—like in the deep skin of your arm and it’s got an infection around it. And all of your coping mechanisms, all of your protectors (using IFS language), is like building a giant layer of scar tissue on top of that. And you could just go through life with that, and you could just put lotion on the top of that scar and just try to make it look pretty—and that’s okay. But you could go in and surgically remove the sliver that’s been offending your system the whole time. And once you remove that sliver, you will start to heal—your arm will heal, it won’t have an infection anymore, right? But removing that sliver hurts. It’s painful. It’s a process. But you don’t have to deal with that sliver anymore. And that’s kind of how I imagine going through trauma work.” [31:08] “I’ve had clients that I’ve worked with using EMDR, IFS for years, we’ve made some progress, but then we get ketamine on board and it’s totally helped them and amplified the benefit.” [35:13] “Trust your protector system. Slow down. I promise, if you slow down and really get curious about what your protectors need, you will go so much further with these medicines. It really is not a race. It’s slow and steady, and you’re going to be able to get more work done.” [40:23] Links: Sunny’s website Sunny on LinkedIn Sunny on Instagram Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick Brüss, EdD, LMFT Psychedelic Medicine Association Porangui
    Más Menos
    46 m
  • Encore episode: Psychedelics and the LGBTQIA2S+ Community with Dr. Angela Carter

    Encore episode: Psychedelics and the LGBTQIA2S+ Community with Dr. Angela Carter
    Jun 5 2024

    This episode of the Plant Medicine Podcast welcomes Dr. Angela Carter (they/them) to discuss the intersection of the LGBTQIA2S+ community and psychedelics. Dr. Carter is a queer, transgender, and genderqueer naturopathic primary care physician who also works as a midwife, sexual assault examiner, and health equity advocate in Portland, Oregon. They also serve as both the vice-chair and the equity in training subcommittees co-chair of the Oregon Psilocybin Advisory Board. In addition to these positions, Dr. Carter serves as the chair of the Transgender Health Program Community Advisory Board at Oregon Health & Science University. They also volunteer with many organizations including the Fireside Project, Black Rock City Emergency Services, and Queerdome.

    Dr. Carter begins this conversation by sharing exciting new research currently being conducted which involves LGBTQIA2S+ individuals and psychedelic therapies. While this particular area of research remains small, it is growing and the fruits of these studies will be an important step for better understanding how these new therapies can serve gender and sexuality minorities, and help facilitators understand the unique concerns of people in the LGBTQIA2S+ community. Dr. Carter illustrates these types of concerns by discussing the prevalence of gender binaries within psychedelic spaces. They describe how in a clinical setting it is prevalent to have both a male and a female facilitator, but this leaves no room for gender-nonconforming people to guide experiences—something which could be preferable if the patient themselves shares this identity.

    Dr. Carter also discusses this gender binary in traditional contexts. It is common for ayahuasca ceremonies to provide separate spaces for men and women, again leaving no space for gender-nonconforming people. This reification of the gender binary and the often patriarchal organization of the ayahuasca ceremony can have serious impacts on the set and setting, especially for people in the LGBTQIA2S+ community. Dr. Carter emphasizes the importance of making space for folks in the community so that they are able to receive therapy, attend ceremonies, and participate in integration with others who share similar identities. This shared identity, they emphasize, ensures that LGBTQIA2S+ people don’t feel out of place in contexts that ought to be healing. Dr. Carter closes by discussing how members of the LGBTQIA2S+ community experience disproportionate rates of mental illness, further illustrating the crucial importance of equity in accessing psychedelic medicine.

    In this episode:

    • Problems of representation and access for LGBTQIA2S+ individuals in the psychedelic space
    • Current research being done on the intersection between psychedelic therapies and unique issues faced by gender and sexuality minorities
    • Preparations to take before guiding a psychedelic experience for LGBTQIA2S+ people, particularly if you do not come from the community
    • How plant medicines could have unique benefits for the LGBTQIA2S+ community
    • Issues of poverty faced by marginalized peoples and how to support equity of access to emerging psychedelic therapies

    Quotes:

    “For some people that idea of melding, of becoming one and losing all of those unique pieces of themselves, doesn’t fit their paradigm of a spiritual connecting experience.” [10:47]

    “It’s precious, that centering of our community—to be able to sit with people who just understand.” [19:42]

    “Psychedelics offer the opportunity for connection of the self to something greater, something outside, a bigger community, spirituality, and really do a huge amount to heal peoples’ relationships with substances.” [25:20]

    “Marginalized communities have been really impacted, largely, by the war on drugs, which has put millions of people in jail for drug offenses and stolen their ability to make income, stolen their ability to connect with community and we really need to heal that.” [33:34]

    Links:

    Chacruna Institute Queering Psychedelics 2019 Conference

    Queerdome on Facebook

    Portland Psychedelic Society

    Psychedelic Medicine Association

    Porangui
    Más Menos
    38 m
  • The Potential of Non-Dissociative Ketamine with Hans Eriksson MD, PhD, MBA

    The Potential of Non-Dissociative Ketamine with Hans Eriksson MD, PhD, MBA
    May 22 2024

    In this episode of the Psychedelic Medicine Podcast, Dr. Hans Eriksson joins to discuss the potential of non-dissociative ketamine. Dr. Eriksson, Chief Medical Officer at HMNC Brain Health, is a highly respected drug developer and clinical psychiatrist with over 20 years of pharmaceutical experience. Prior to HMNC Brain Health, Dr. Eriksson served as Chief Medical Officer at COMPASS Pathways and previously as Senior Director of Clinical Research at Lundbeck and Medical Science Director at AstraZeneca.

    In this conversation, Dr. Eriksson shares what inspired him to move from clinical practice to drug development, and why he sees so much potential in developing non-dissociative forms of ketamine. He discusses the ways the dissociative effects of ketamine decrease the accessibility of this treatment due to the fact that these changes in perception are undesirable for a significant portion of patients. Dr. Eriksson also shares results from preliminary studies of non-dissociative ketamine which showed efficacy in inducing anti-depressant effects. In closing, Dr. Eriksson discusses why he thinks the experiential element of the classical psychedelics play an important role in their efficacy as mental health treatments, but why this might not be the case when it comes to ketamine.

    In this episode you'll hear:

    • The history of ketamine
    • The pharmacology of ketamine’s dissociative effect
    • The relationship between ketamine dose and antidepressant effect
    • The possibility of bladder issues and addiction with ketamine and whether non-dissociative forms of ketamine would also have these potentials
    • How Dr. Eriksson thinks about combining psychotherapy with ketamine treatments

    Quotes:

    “We are aiming for a similar exposure to the drug as you achieve with, for instance, an intravenous administration, but we are achieving a much lower peak concentration, maximum concentration of the compound. So that is one of the characteristics of our formulation.” [10:58]

    “Our view is that it's probably better to try to use the metabolism in the body as a tool to achieve very low exposure to ketamine but high exposure to the downstream metabolites.” [23:19]

    Links:

    Dr. Eriksson on LinkedIn

    HMNC Brain Health on LinkedIn

    HMNC Brain Health website

    Previous episode: Potential Benefits of Non-Hallucinogenic Psychedelics with Kurt Rasmussen, PhD

    Psychedelic Medicine Association

    Porangui
    Más Menos
    31 m
Enfermedades Físicas Psicología Hygiene & Healthy Living
Más Menos

Lo que los oyentes dicen sobre Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles